Biologic and Molecular Prognostic Factors—Impact on Treatment of Patients With Non-small Cell Lung Cancer
- 1 June 1995
- Vol. 107 (6), 287S-290S
- https://doi.org/10.1378/chest.107.6_supplement.287s
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.Journal of Clinical Oncology, 1994
- Prognostic impact of histologic demonstration of Chromogranin A and Neuron Specific Enolase in pulmonary adenocarcinomaAnnals of Oncology, 1991
- K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the LungNew England Journal of Medicine, 1990
- The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.Journal of Clinical Oncology, 1989
- Inhibition of Growth of Human Lung Adenocarcinoma Cell Lines by Anti-Transforming Growth Factor- Monoclonal AntibodyJNCI Journal of the National Cancer Institute, 1989
- Human epidermal growth factor precursor: cDNA sequence, expressionin vitroand gene organizationNucleic Acids Research, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.Proceedings of the National Academy of Sciences, 1985
- Human transforming growth factor-α: Precursor structure and expression in E. coliCell, 1984
- Autocrine Secretion and Malignant Transformation of CellsNew England Journal of Medicine, 1980